Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotic-antibiotic Combination to Prevent Recurrent UTIs
NCT06149676Phase 1Completed
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Start
- Feb 2022
- Primary completion
- Dec 2024
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of saccharomyces boulardii and ciprofloxacin in urinary tract infection (UTI) (2 arms), sponsored by Ann & Robert H Lurie Children's Hospital of Chicago. Primary endpoint: Reduction in UTI episodes at 6 months. Started Feb 2022; status: completed.
02
Drugs
saccharomyces boulardiiciprofloxacin
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on NCT06149676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06149676.